SynaptixBio and Evotec extend rare disease therapies partnership
Drug Discovery World
JULY 24, 2024
The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research, under a sponsored research agreement. CHOP identified a candidate antisense oligonucleotide (ASO) as a potential therapy for H-ABC.
Let's personalize your content